How TailorMed, Tennr Aim to Speed Specialty Access

TailorMed and Tennr announced a partnership integrating their platforms to connect referral automation with medication access and affordability support, a move the companies say is designed to help infusion centers and specialty pharmacies identify care barriers earlier and start patients on treatment faster.¹

The collaboration pairs Tennr's referral intake, documentation review and access workflow automation with TailorMed's affordability and ongoing-support tools.¹ The companies will begin with an integration, with Pure Infusion as the first customer, that they say will create a more connected access infrastructure so teams can identify care barriers earlier and move patients toward treatment faster.

The tie-up reflects a broader movement in pharmacy care toward connected technology infrastructure that supports care teams and patients across traditionally fragmented access, intake, affordability and adherence workflows.

What Problem Is the Integration Trying to Solve?

The companies frame the gap between a referral and the start of therapy as a primary point where patients stall, often over cost uncertainty.

"Our work has always been about getting patients care faster," said Trey Holterman, CEO of Tennr, in the announcement.¹ "The biggest reason we see patients not getting access to medication is fear and uncertainty around what the medication will cost them personally and what resources they have at their disposal to cover those costs."

Srulik Dvorsky, CEO of TailorMed, positioned the integration as joining two halves of the same workflow. "Getting a patient referred and empowering them to succeed in their medication journey are two halves of the same problem," he said. "Tennr has built remarkable technology for the first half and we've built a vast network and robust solution set for the second. Bringing the pieces together means fewer patients falling in the gap between a referral and the start of care."

Pure Infusion said the arrangement is meant to reduce friction in moving patients into treatment. “Our patients need to access care quickly, barrier-free,” added Brady Porter, chief commercial officer, at Pure Infusion.¹

How Large Is the Access-and-Affordability Gap?

Industry data point to significant patient drop-off between prescription and treatment, particularly for high-cost therapies. Nearly two-thirds of prescriptions for newly launched drugs go unfilled in the first year on the market, according to IQVIA's US Medicine Use Trends 2026 report.² Across 99 novel medicines launched from 2020 to 2024, an average of 35% of first-year prescriptions were filled while 65% went unfilled, including 49% rejected by payers and 17% abandoned by patients after approval, likely because of high out-of-pocket costs.

Both failure points are what the TailorMed-Tennr integration is aimed at, pairing referral and documentation automation that can reduce payer rejections with affordability support for patients who clear approval but stall at the point of cost.

Why Does This Matter for the Access Channel?

The integration is the latest sign of consolidation among the technology layers that sit between a prescription and the pharmacy, as referral, intake, affordability and adherence functions increasingly move onto shared infrastructure rather than operating as separate point solutions.

It also follows a similar move by TailorMed weeks earlier. In June, the company announced a partnership with WeInfuse, a software platform for infusion providers and specialty pharmacies, to embed its medication access network directly into WeInfuse workflows.³ Two access-infrastructure agreements targeting the infusion and specialty setting inside a two-week span underscore how quickly affordability tooling is being wired into upstream referral and intake systems.

References

1. TailorMed and Tennr. "TailorMed and Tennr Announce Collaboration to Streamline Patient Medication Workflows." Press release received July 9, 2026.
2. IQVIA Institute for Human Data Science. "U.S. Medicine Use Trends 2026." IQVIA, Apr. 28, 2026. https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/us-medicine-use-trends-2026
3. WeInfuse. "WeInfuse Announces Partnership with TailorMed to Remove Systematic Medication Barriers for Infusion Patients." June 30, 2026. tailormed.com. https://www.tailormed.com/news-blogs/tailormed-and-weinfuse-partner-to-expand-infusion-access